Skip to main content

Marine Bouaziz

Associate

[email protected]

+1.212.692.6236

Share:

Marine’s practice focuses on corporate and securities matters with an emphasis on securities offerings, venture capital, and corporate governance.       

Marine represents start-ups and emerging companies, venture funds, private equity investors, and family offices in private securities transactions, including early and late-stage equity financings, convertible debt, and other structures. As an advisor to start-ups and emerging companies, Marine provides day-to-day counseling and strategic advice, and regularly counsels clients on all issues and transactions that arise during a company’s lifecycle, such as those involving strategic alliances, technology transactions, and exit/M&A.     

Additionally, Marine counsels investment advisors with respect to the structuring, formation, and operations of private funds, including venture capital, private equity, and hedge funds.

Committed to pro bono initiatives throughout her legal career, Marine’s pro bono experience includes representing indigent parties in the Bronx, New York, Kings, Queens and Richmond County Family Courts.

Prior to joining Mintz, Marine worked in London for a company that serves entrepreneurs. She also completed legal internships in Paris and Singapore during law school.

Marine is a native French speaker.

viewpoints

This alert looks at recent SEC communications providing guidance on — and limiting the use of — digital tokens.
Read more
This article explains why the “cryptocurrency” label can be misleading, and suggests we use “virtual currencies,” “security tokens,” and “utility tokens” instead.
Read more
Read less

News & Press

Press Release Thumbnail
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.
Read less